The Discounted Cash Flow (DCF) valuation of Nektar Therapeutics (NKTR) is (138.57) USD. With the latest stock price at 72.22 USD, the upside of Nektar Therapeutics based on DCF is -291.9%.
Based on the latest price of 72.22 USD and our DCF valuation, Nektar Therapeutics (NKTR) is a sell. selling NKTR stocks now will result in a potential gain of 291.9%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.7% - 8.9% | 7.8% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (292.21) - (93.87) | (138.57) |
| Upside | -504.6% - -230.0% | -291.9% |